Vanguard Group Inc Entrada Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
A detailed history of Vanguard Group Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,604,225 shares of TRDA stock, worth $13.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,604,225
Previous 1,604,860
0.04%
Holding current value
$13.6 Million
Previous $10.8 Million
13.72%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding TRDA
# of Institutions
117Shares Held
27.9MCall Options Held
13.7KPut Options Held
14K-
Baker Bros. Advisors LP New York, NY4.87MShares$41.2 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$37.1 Million56.82% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.26MShares$36.1 Million16.56% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$14.3 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA954KShares$8.08 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $266M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...